IL6 and COVID-19: Compared to both healthy controls and patients with viral or bacterial pneumonia, COVID-19 patients, especially severe cases, have in their peripheral blood reduced numbers of CD14+CD16-DR+ “classical” monocytes, which may be due to the increased levels of IL-6 and/or dysregulated myelopoiesis [1,4,65–68].